Tilray investors could probably use a bit of the company’s products right now.
The maker of cannabis extracts finished a whipsaw session 40 percent higher. That’s a great day for any stock. But Tilray was up as much as 94 percent, peaking at $300.00 at 2:50 p.m. in New York. Fifty-three minutes and four trading halts later, it was negative. The closing flourish that added $63 to the share price took just six minutes.
“It left a sea of bodies, both longs and shorts, behind in its wake,” Dave Lutz, Managing Director at JonesTrading, said by phone.
The stock’s wild ride Wednesday is emblamatic of the mania surrounding pot stocks, drawing comparisons to last year’s crypto craze that sent investors pouring into Bitcoin and its ilk. Tilray rallied to more than 14 times its July initial public offering price, making it one of the best IPOs in the past decade. The company has a market value that exceeds some mainstream stocks, including American Airlines and Clorox.
“It’s like the entire world is trading one stock right now. It’s fun to watch,” Michael Antonelli, an institutional equity sales trader and managing director at Robert W. Baird & Co., said by phone. “It’s the wild west right now for cannabis. Markets have a tough time timing the future with this much uncertainty.”
About $5.9 billion worth of shares traded hands Wednesday, behind only Amazon’s $6.1 billion; the stock’s dramatic move triggered at least four halts for volatility. Tilray soared Tuesday after announcing the U.S. DEA approved plans for it to import medical marijuana to supply a clinical trial in California; the stock has gained 42 percent this week and more than 1,100 percent since its trading debut in July.
- Climate-Conscious Architects Want Europe To Build Less
- The Red-State Governor Who's Not Afraid to Be 'Woke'
- Jonathan Van Ness: We Are Still Not Taking Monkeypox Seriously Enough
- The Not-So-Romantic Return of Europe's Sleeper Trains
- This Filmmaker Set Out To Record Her Family’s Journey Rebuilding Afghanistan. Her Work Is a Reminder of What’s at Stake
- Why Sunscreen Ingredients Need More Safety Data
- What Historians Think of the Joe Biden-Jimmy Carter Comparisons
- Author Mimi Zhu Is Relearning What It Means to Love After Trauma